Journal article
SLC25A22 promotes proliferation and metastasis by activating MAPK/ERK pathway in gallbladder cancer
Cancer cell international, v 19(1), pp 33-33
14 Feb 2019
PMID: 30814911
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
SLC25A22, a member of mitochondrial carrier system (MCS) family encoding a mitochondrial glutamate transporter, has been reported to have vital roles in promoting proliferation and migration in cancer. Gallbladder cancer (GBC) is the most common biliary tract malignancy and has a poor prognosis. We aimed to determine the expression and function of SLC25A22 in GBC.
Immunohistochemistry (IHC) staining analysis and quantitative real-time PCR (qRT-PCR) were conducted to determine the expression of SLC25A22 in GBC tissues. Human NOZ and GBC-SD cells were used to perform the experiments. The protein expression was detected by western-blot analysis. Cell viability was evaluated via CCK-8 assay and colony formation assay. Cell migration and invasion in vitro were investigated by wound healing and transwell assay. Annexin V/PI staining assay for apoptosis were measured by flow cytometry. The effect of SLC25A22 in vivo was conducted with subcutaneous xenograft.
We indicated that the expression of SLC25A22 was significantly upregulated in GBC tumor tissues as well as cell lines. Downregulation of SLC25A22 inhibited GBC cell growth and proliferation in vitro and in vivo and also had an effect on metastasis of GBC cells through the EMT processes. In addition, inhibition of SLC25A22 promoted mitochondrial apoptosis via downregulating BCL-2 and upregulating cleaved PARP, Cytochrome-c, and BAX mediated by MAPK/ERK pathway.
Our study identified that SLC25A22 promoted development of GBC activating MAPK/ERK pathway. SLC25A22 has a potential to be used as a target for cancer diagnosis of GBC and related therapies.
Metrics
Details
- Title
- SLC25A22 promotes proliferation and metastasis by activating MAPK/ERK pathway in gallbladder cancer
- Creators
- Pengcheng Du - Second Affiliated Hospital of Nanchang UniversityHaibin Liang - XinHua HospitalXiaowei Fu - First Affiliated Hospital of Nanchang UniversityPeng Wu - Second Affiliated Hospital of Nanchang UniversityChao Wang - Second Affiliated Hospital of Nanchang UniversityHaimin Chen - Second Affiliated Hospital of Nanchang UniversityBingbing Zheng - Second Affiliated Hospital of Nanchang UniversityJun Zhang - Second Affiliated Hospital of Nanchang UniversityShuanghui Hu - Second Affiliated Hospital of Nanchang UniversityRengui Zeng - Second Affiliated Hospital of Nanchang UniversityBo Liang - Second Affiliated Hospital of Nanchang UniversityLu Fang - Second Affiliated Hospital of Nanchang UniversityHualou Liang - School of Biomedical Engineering, Science, and Health Systems (1997-)
- Publication Details
- Cancer cell international, v 19(1), pp 33-33
- Publisher
- Springer Nature
- Number of pages
- 10
- Grant note
- 81760438 / Natural Science Foundation of Nation, China GJJ150260 / Education Department of Jiangxi Province 20171BBG70063 / Key Research Project of Jiangxi Province, China CX2017204 / Innovation Research Foundation of Graduate School of Nanchang University
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems
- Web of Science ID
- WOS:000459083200002
- Scopus ID
- 2-s2.0-85061557460
- Other Identifier
- 991019320403404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology